MENA Launches First Centre For Advanced Neuro Biochemical Diagnostics To Enhance Alzheimer's Detection

The National Reference Laboratory (NRL), part of the M42 Group, is collaborating with Neurocode International to establish the first Centre for Advanced Neuro Biochemical Diagnostics in the MENA region. This centre, located in Abu Dhabi, focuses on early detection of neurological disorders, particularly Alzheimer's disease. Announced during Abu Dhabi Global Health Week, this initiative aims to reduce Alzheimer's cases in the UAE and beyond.

Alzheimer's disease is a significant health concern worldwide, affecting over 57 million people as of 2021. It represents the most prevalent form of dementia, accounting for 60-70% of cases. Early detection is essential for managing symptoms and slowing progression. However, traditional methods are invasive and often involve spinal cord procedures, leading to low early detection rates.

The Centre for Advanced Neuro Biochemical Diagnostics plans to transform Alzheimer's diagnosis by offering blood-based tests starting at age 40. This approach aims to facilitate timely intervention and improve patient outcomes significantly. Hasan Jasem Al Nowais, Managing Director and Group CEO of M42, stated that the centre will "revolutionise the early, proactive detection of Alzheimer's," highlighting their commitment to preventive health.

The centre's goal is to create the world's most advanced clinical diagnostic laboratory for brain disorders. It will guide global clinicians in precision detection and usher in a new era of neurological diagnostics. Research findings will be shared with the medical community through top scientific journals.

Dr. Laila AbdelWareth, CEO of NRL, emphasised that establishing this centre marks a pivotal moment in combating Alzheimer's and other neurological disorders. The focus will be on advancing preventive health through precision detection. Expert-led research will be central to the centre's mission.

A full-time lab-based professor of neurology with dementia training from Gothenburg University will lead research efforts. Prof. Henrik Zetterberg and Prof. Kaj Blennow, both experts in Alzheimer's biomarkers and early diagnostic tools development, will serve as off-site consultants.

Global Impact and Vision

Dr. Hans Frykman, CEO of Neurocode International, expressed excitement about partnering with NRL to establish a leading clinical laboratory for brain disorders. He noted that their team comprises some of the most experienced scientists in the field who aim to guide physicians globally toward accurate diagnoses.

This initiative not only marks a first for the MENA region but also signifies a new era in global Alzheimer's research. By focusing on proactive prevention, the Centre for Advanced Neuro Biochemical Diagnostics seeks to redefine care standards and reduce Alzheimer's prevalence significantly in the UAE and beyond.

The laboratory will provide world-class technology and infrastructure to ensure standardised test levels across leading labs for consistent care quality. This effort underscores a commitment to enhancing patient outcomes through innovative diagnostic solutions.

With inputs from WAM